ClinicalTrials.gg
RecruitingNCT06574360Updated Mar 24, 2026

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

A Phase 2 interventional study of S1RA plus NMDAE and S1RA plus Placebo Cap in Schizophrenia, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Schizophrenia by China Medical University Hospital — 8 open to participants now, 8 under way, none of them phase 3. Schizophrenia · China Medical University Hospital.

Planned enrollment
Largest of 14
90 · median 60
Started
2024
the only one that year
Phase 2
14 of 15
8 open now
Registered
14th of 15
by date

Among the 15 studies in Schizophrenia by China Medical University Hospital, this one has the largest planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 14 in phase 2, and was the 14th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

8 of the 15 studies in Schizophrenia by China Medical University Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Schizophrenia by China Medical University Hospital, or all of them as a file.
02

Study summary

sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.

Read the detailed description

The current treatment for schizophrenia remains unsatisfactory; thus, development of new treatments is vital. Both sigma-1 receptor (S1R) dysfunction and NMDA receptor (NMDAR) hypofunction contribute to pathogenesis of schizophrenia, especially treatment-resistant schizophrenia. Several S1R agonists have been tested for its potential for schizophrenia treatment; however, its efficacy appears limited. In addition, previous studies also found that some NMDA-enhancing agents were able to augment efficacy of antipsychotics in the treatment of chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancer (NMDAE) can be better than an S1R agonist alone deserves study. Therefore, this study aims to compare an S1R agonist plus an NMDAE and an S1R agonist plus placebo in the treatment of treatment-resistant schizophrenia. The subjects are the patients with treatment-resistant schizophrenia who have responded poorly to two or more kinds of antipsychotics treatment. They keep their original treatment and are randomly, double-blindly assigned into two treatment groups for 12 weeks: (1) S1R agonist (S1RA) plus NMDAE, or (2) S1RA plus placebo. Clinical performances and side effects are measured at weeks 0, 2, 4, 6, and 8. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. The efficacies of S1RA plus NMDAE and S1RA plus placebo will be compared.

Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • NMDA
  • sigma-1 receptor
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (American Psychiatric Association) diagnosis of schizophrenia
  • Are resistant to adequate treatments of at least two antipsychotics (excluding clozapine)
  • Remain symptomatic but without fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 8-week trial
  • PANSS total score >70
  • Hamilton Depression Rating Scale-17 items (HAMD) \<7
  • Are physically healthy and laboratory assessments (including blood routine, biochemical tests) are clinically insignificant.
  • Have sufficient education to communicate effectively and are capable of completing the assessments of the study.
  • Agree to participate in the study and provide

Exclusion criteria

Exclusion Criteria:

  • diagnosis of intellectual disability or substance (including alcohol) use disorder
  • History of epilepsy, head trauma, central nervous system diseases or mental disorders other than schizophrenia (including major depressive disorder, bipolar disorders, persistent depressive disorder, obsessive-compulsive disorder)
  • Pregnancy or lactation
  • Inability to follow protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    S1R agonist (S1RA) plus NMDAE

    An S1R agonist plus an NMDA enhancer

    Drug: S1RA plus NMDAE

  • Placebo comparator
    S1R agonist (S1RA) plus placebo

    An S1R agonist plus placebo

    Drug: S1RA plus Placebo Cap

Interventions

  • DrugS1RA plus NMDAE

    Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.

  • DrugS1RA plus Placebo Cap

    Use of an S1R agonist plus placebo as a comparator

06

What researchers measure

Primary outcomes

  1. Change of Positive and Negative Syndrome Scale (PANSS)

    Assessment of overall symptoms. Minimum value: 30, maximum value:210, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

Secondary outcomes

  1. Change of scales for the Assessment of Negative Symptoms (SANS) total score

    Assessment of negative symptoms. Minimum value: 0, maximum value:100, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

  2. Positive subscale, Negative subscales, and General Psychopathology subscale of PANSS

    PANSS-positive: Assessment of positive symptoms. Minimum value: 7, maximum value:49, the higher scores mean a worse outcome. PANSS-negative: Assessment of negative symptoms. Minimum value: 7, maximum value:49, the higher scores mean a worse outcome. PANSS-general psychopathology: Assessment of general psychopathology. Minimum value: 16, maximum value:112, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

  3. Clinical Global Impression

    Assessment of general impression. Minimum value: 1, maximum value:7, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

  4. Global Assessment of Functioning

    Assessment of social, occupational, and psychological function. Minimum value: 1, maximum value:100, the higher scores mean better function.

    Time frame: week 0, 2, 4, 6, 8

  5. Quality of Life Scale

    Assessment of life quality. Minimum value: 0, maximum value:126, the higher scores mean a better outcome.

    Time frame: week 0, 2, 4, 6, 8

  6. Cognitive function

    Ten tests for assessment of 7 cognitive domains: 1. speed of processing (assessed by Category Fluency, Trail Marking A, Wechsler Adult Intelligence Scale(WAIS)-III Digit Symbol-Coding) 2. sustained attention (Continuous Performance Test) 3. working memory: verbal (digit span) and nonverbal (spatial span) 4. verbal learning and memory (WMS-III, word listing) 5. visual learning and memory (WMS-III, visual reproduction) 6. reasoning and problem solving (WISC-III, Maze) 7. social cognition (MSCEIT Version 2) For the domain (a. and c.) with more than one test, a composite T score will be calculated by standardizing the average of each T score. Furthermore, a global composite score (for all seven domains) and a neurocognitive composite score (for the first 6 domains) will be also calculated by standardizing the average of the T score (Lane HY et al, JAMA Psychiatry 2013)

    Time frame: Week 0, 8

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2028, 51 months after the start.

Of 44 non-industry phase 2 interventional studies under Schizophrenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's planned 51 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Aug 27, 2024
StartActual
Sep 23, 2024
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06574360
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Sep 23, 2024
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Mar 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion